Home›Trial›NCT04736173
🔬NCT04736173Phase 2ACTIVE NOT RECRUITING

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Study Summary

This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).

Conditions
Non Small Cell Lung CancerNonsquamous Non Small Cell Lung CancerSquamous Non Small Cell Lung CancerLung Cancer
Interventions / Drugs
DomvanalimabZimberelimabCarboplatinPaclitaxelPemetrexedPembrolizumab
View on ClinicalTrials.gov ↗
Sponsor
ARQT
Arcus Biosciences
Immuno-Oncology
F29/100
Study Details
Enrollment169 participants
Primary Completion—
Lead SponsorArcus Biosciences, Inc.
Data Retrieved2026-04-11 02:54:25.662840+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.